Helix BioPharma Corp. Close Private Placement

(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units totalling aggregate gross proceeds of approximately CAD1.82 million and had closed on CAD1.58 million.

Helix BioPharma Corp. Successfully Out-Licenses Late Stage BiPhasix Technology

(Toronto, Ontario) – Helix BioPharma Corp. (“Helix” or the “Company”) (TSX, FSE: “HBP”), a clinical stage, immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces today it has signed an exclusive out-license agreement with Xisle Pharma Ventures Trust (“Xisle”) for the Company’s late-stage, Biphasix™ technology platform, including the lead product candidate, interferon alpha. Xisle will …

Helix Biopharma Corp. To Present at the Biotech Showcase Conference During the Annual JP Morgan Week in San Francisco

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, intends to meet a selection of Big Pharma and Big Biotech companies during the Annual JP Morgan Conference week in San Francisco during January 9-12, 2017.  In addition, Helix has been selected to present …

Helix BioPharma Corp. Presents Topline L-DOS47 Results at the 17th IASCLC World Conference on Lung Cancer

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announce that it presented topline data from its phase I/II dose escalation study of immunoconjugate LDOS47 as a monotherapy in non-squamous non-small cell lung cancer patients at the 17th IASCLC World Conference on Lung …

Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the US Phase I Study

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in nonsquamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration (“FDA”) has accepted an accelerated …

Helix BioPharma Corp. Announces Poster Presentation of L-DOS47 at the World Conference on Lung Cancer

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients has been selected for poster presentation at …

Helix BioPharma Corp. Announces Fiscal 2016 Results

(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2016.

Helix BioPharma Corp Presents At National Investment Banking Association

(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the National Investment Banking Association (“NIBA”) conference on Thursday October 27, 2016 at 10:45am …